Jean-Philippe has 28 years of experience in the pharma & biotech industries. He is a highly skilled senior executive with a broad range of experience leading global development and a successful track record of partnership, innovation and development in the area of Orphan Drugs. Co-Founder of Vivet in 2016, he lead the Series A of 37,5M€ and recent collaboration and option deal with Pfizer in March 2019. While Chief Operating Officer of GenSight Biologics (2014-2017), he successfully contributed and participated to investment round of more than 80M$, including a successful IPO and piloted the advancement of two major gene therapy programs from non-clinical to phase 3 pivotal trials, as well as regulatory and launch readiness strategies. Prior to his GenSight experience, from 2011 to 2014, he was Strategic Therapeutic Area Leader at Galderma extending from the preclinical stage through launch readiness activities and assessment of business development opportunities and prior to that held the role of Vice President of Drug Development at Sanofi (Ophthalmic Division after Fovea Pharmaceuticals acquisition; 2006-2011). During his early career, from 1990 to 2006, Jean-Philippe was a key leader in the research and development departments at Servier, Pierre Fabre, Fournier-Pharma/Solvay, Exonhit Therapeutics. Jean-Philippe earned his PhD in Toxicology and Pharm.D from Paris XI University and General Management Program from center of executive development at INSEAD.